The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin
- PMID: 29244074
- PMCID: PMC6927890
- DOI: 10.1093/eurheartj/ehx679
The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin
Abstract
Aims: Heart failure (HF) is accompanied by major neuroendocrine changes including the activation of the natriuretic peptide (NP) pathway. Using the unique model of patients undergoing implantation of the CARMAT total artificial heart and investigating regional differences in soluble neprilysin (sNEP) in patients with reduced or preserved systolic function, we studied the regulation of the NP pathway in HF.
Methods and results: Venous blood samples from two patients undergoing replacement of the failing ventricles with a total artificial heart were collected before implantation and weekly thereafter until post-operative week 6. The ventricular removal was associated with an immediate drop in circulating NPs, a nearly total disappearance of circulating glycosylated proBNP and furin activity and a marked decrease in sNEP. From post-operative week 1 onwards, NP concentrations remained overall unchanged. In contrast, partial recoveries in glycosylated proBNP, furin activity, and sNEP were observed. Furthermore, while in patients with preserved systolic function (n = 6), sNEP concentrations in the coronary sinus and systemic vessels were similar (all P > 0.05), in patients with reduced left-ventricular systolic function, sNEP concentration, and activity were ∼three-fold higher in coronary sinus compared to systemic vessels (n = 21, all P < 0.0001), while the trans-pulmonary gradient was neutral (n = 5, P = 1.0).
Conclusion: The heart plays a pivotal role as a regulator of the endocrine response in systolic dysfunction, not only by directly releasing NPs but also by contributing to circulating sNEP, which in turn determines the bioavailability of other numerous vasoactive peptides.
Figures
Comment in
-
Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics?Eur Heart J. 2018 Oct 1;39(37):3472-3473. doi: 10.1093/eurheartj/ehy454. Eur Heart J. 2018. PMID: 30060054 No abstract available.
-
Plasma neprilysin concentration during recovery from acute illness.Eur Heart J. 2018 Oct 1;39(37):3474-3475. doi: 10.1093/eurheartj/ehy456. Eur Heart J. 2018. PMID: 30060107 No abstract available.
References
-
- Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K.. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195–203. - PubMed
-
- Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Ishihara S, Cohen Solal A, Januzzi JL Jr, Richards AM, Launay JM, Mebazaa A, Network G.. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J 2014;35:3434–3441. - PubMed
-
- Ichiki T, Burnett JC Jr.. Post-transcriptional modification of pro-BNP in heart failure: is glycosylation and circulating furin key for cardiovascular homeostasis? Eur Heart J 2014;35:3001–3003. - PubMed
-
- Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL Jr, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Cohen-Solal A, Richards AM, Launay JM, Mebazaa A, Network G.. Elevated plasma B-Type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail 2015;3:629–636. - PubMed
-
- Bayes-Genis A, Barallat J, Richards AM.. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol 2016;68:639–653. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
